Home › Research › Caregiving
Therapeutics of Alzheimer's disease: Past, present and future
Anand R, Gill KD, Mahdi AA.. Neuropharmacology, 2013-07-25
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD) is the most common cause of dementia worldwide. The etiology is multifactorial, and pathophysiology of the disease is complex. Data indicate an exponential rise in the number of cases of AD, emphasizing the need for developing an effective treatment. AD also imposes tremendous emotional and financial burden to the patient's family and community. The disease has been studied over a century, but acetylcholinesterase inhibitors and memantine are the only drugs currently approved for its management. These drugs provide symptomatic improvement alone but do less to modify the disease process. The extensive insight into the molecular and cellular pathomechanism in AD over the past few decades has provided us significant progress in the understanding of the disease. A number of novel strategies that seek to modify the disease process have been developed. The major developments in this direction are the amyloid and tau based therapeutics, which could hold the key to treatment of AD in the near future. Several putative drugs have been thoroughly investigated in preclinical studies, but many of them have failed to produce results in the clinical scenario; therefore it is only prudent that lessons be learnt from the past mistakes. The current rationales and targets evaluated for therapeutic benefit in AD are reviewed in this article. This article is part of the Special Issue entitled 'The Synaptic Basis of Neurodegenerative Disorders'.
What this study adds
Evidence grade: Low
This is a narrative review. This review notes that only acetylcholinesterase inhibitors and memantine are currently approved, and these give symptom relief rather than modifying the disease. It describes amyloid- and tau-based approaches as still under development, with many candidate drugs having failed in clinical testing.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Anand, R., Gill, K. D., & Mahdi, A. A. (2014). Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2013.07.004
Vancouver
Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer's disease: Past, present and future. Neuropharmacology. 2014. doi:10.1016/j.neuropharm.2013.07.004. PMID: 23891641.
BibTeX
@article{anand2014-23891641,
author = {Anand, R. and Gill, K. D. and Mahdi, A. A.},
title = {{Therapeutics of Alzheimer's disease: Past, present and future}},
journal = {Neuropharmacology},
year = {2014},
doi = {10.1016/j.neuropharm.2013.07.004},
pmid = {23891641},
url = {https://doi.org/10.1016/j.neuropharm.2013.07.004}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The extensive insight into the molecular and cellular pathomechanism in AD over the past few decades has provided us significant progress in the understanding of the disease.
- Several putative drugs have been thoroughly investigated in preclinical studies, but many of them have failed to produce results in the clinical scenario; therefore it is only prudent that lessons be learnt from the past mistakes.
Why it matters
This review notes that only acetylcholinesterase inhibitors and memantine are currently approved, and these give symptom relief rather than modifying the disease. It describes amyloid- and tau-based approaches as still under development, with many candidate drugs having failed in clinical testing.
New to this subject? Start with our plain-English guide: Caregiving →
Study details
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neuropharmacology) |
| Journal's citation record | 2 / 4 | Neuropharmacology: journal h-index 246 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2014 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 750 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 53.6 citations a year over 14 year(s) since 2014 |
| Impact for its field and year | 5 / 6 | Cited 27.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 9 other studies in this library |
| Still being cited | 3 / 4 | Cited 92 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Abbas Ali Mahdi: h-index 48 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Post Graduate Institute of Medical Education and Research: institution h-index 351 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 23891641) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 55.
Later studies that cite this one
9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Caregiving from nearby years
Also in Caregiving
69 studies in the library are filed under Caregiving with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Caregiving hub.